123,372 research outputs found
Avaliação do rastreamento para câncer de prostata em homens com antígeno prostático específico menor que 3,0 ng/ml.
No full textTrabalho de Conclusão de Curso - Universidade Federal de Santa Catarina. Curso de Medicina. Dapartamento de Clínica Cirúrgica
(a) AF MMP-8 concentrations and (b) umbilical cord plasma CRP concentrations at birth according to PTL or preterm-PROM in the context of placenta without inflammatory lesion (AF MMP-8: PTL, median, 9.5 ng/ml [range, 0.3–1454.5 ng/ml] vs. preterm-PROM, median, 9.1 ng/ml [range, 0.3–3222.9 ng/ml]; umbilical cord plasma CRP: PTL, median, 21.9 ng/ml [range, 0.2–2143.3 ng/ml] vs. preterm-PROM, median, 14.7 ng/ml [range, 0.3–522.7 ng/ml]; each for p = NS).
No full text<p>(a) AF MMP-8 concentrations and (b) umbilical cord plasma CRP concentrations at birth according to PTL or preterm-PROM in the context of placenta without inflammatory lesion (AF MMP-8: PTL, median, 9.5 ng/ml [range, 0.3–1454.5 ng/ml] vs. preterm-PROM, median, 9.1 ng/ml [range, 0.3–3222.9 ng/ml]; umbilical cord plasma CRP: PTL, median, 21.9 ng/ml [range, 0.2–2143.3 ng/ml] vs. preterm-PROM, median, 14.7 ng/ml [range, 0.3–522.7 ng/ml]; each for p = NS).</p
Fluoxetine (ng/ml) and norfluoxetine (ng/ml) levels in blood plasma.
No full text<p>Fluoxetine (ng/ml) and norfluoxetine (ng/ml) levels in blood plasma.</p
Method validation for SPE-HPLC-MS/MS analysis of four cobalamins: Precision and recovery values at different concentrations (0 ng/ml, 0.2 ng/ml, 1.0 ng/ml and 4.0 ng/ml) in quality control samples.
No full textMethod validation for SPE-HPLC-MS/MS analysis of four cobalamins: Precision and recovery values at different concentrations (0 ng/ml, 0.2 ng/ml, 1.0 ng/ml and 4.0 ng/ml) in quality control samples.</p
TCF linearity 2–1,000 ng/mL.
No full textThe TCF assay is linear from 2–1,000 ng cfDNA/mL plasma. The adjusted linear fit equation is ng/mL (y) = -0.455701 + 1.2255499*Expected ng/mL(x).</p
Serum 25(OH)D (ng/mL), D binding protein (DBP) (ng/mL), free (pg/mL) and bioavailable (ng/mL) vitamin D in Systemic Lupus Erythematosus patients, according to disease activity measured by Systemic Lupus Erythematosus Disease Activity Index (SLEDAI).
No full textSerum 25(OH)D (ng/mL), D binding protein (DBP) (ng/mL), free (pg/mL) and bioavailable (ng/mL) vitamin D in Systemic Lupus Erythematosus patients, according to disease activity measured by Systemic Lupus Erythematosus Disease Activity Index (SLEDAI).</p
Cumulative ongoing pregnancy rates for patients with AMH level of 0.2–1 ng/ml or ≤0.2 ng/ml.
No full text<p>Cumulative ongoing pregnancy rates for patients with AMH level of 0.2–1 ng/ml or ≤0.2 ng/ml.</p
Maternal serum levels of PFASs (ng/ml) and OCs (ng/ml and ng/g lipids) in the SGA study (N = 424).
No full textMaternal serum levels of PFASs (ng/ml) and OCs (ng/ml and ng/g lipids) in the SGA study (N = 424).</p
Overlaid MRM chromatograms of fifteen calibration standards of DMB (2–500 ng/mL) and IS (100 ng/mL).
No full textOverlaid MRM chromatograms of fifteen calibration standards of DMB (2–500 ng/mL) and IS (100 ng/mL).</p
(a) AF MMP-8 concentrations and (b) umbilical cord plasma CRP concentrations at birth according to PTL or preterm-PROM in the context of acute- HCA but without funisitis (AF MMP-8: PTL, median, 175.4 ng/ml [range, 1.1–4202.7 ng/ml] vs. preterm-PROM, median, 124.0 ng/ml [range, 0.3–1873.5 ng/ml]; umbilical cord plasma CRP: PTL, median, 37.0 ng/ml [range, 2.9–7401.8 ng/ml] vs. preterm-PROM, median, 27.9 ng/ml [range, 5.6–2018.2 ng/ml]; each for p = NS).
No full text<p>(a) AF MMP-8 concentrations and (b) umbilical cord plasma CRP concentrations at birth according to PTL or preterm-PROM in the context of acute- HCA but without funisitis (AF MMP-8: PTL, median, 175.4 ng/ml [range, 1.1–4202.7 ng/ml] vs. preterm-PROM, median, 124.0 ng/ml [range, 0.3–1873.5 ng/ml]; umbilical cord plasma CRP: PTL, median, 37.0 ng/ml [range, 2.9–7401.8 ng/ml] vs. preterm-PROM, median, 27.9 ng/ml [range, 5.6–2018.2 ng/ml]; each for p = NS).</p
- …
